← All trials
NCT05057715
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- Sep 30, 2038
- Completion date
- Sep 30, 2038
- First posted
- Sep 27, 2021
- Last posted
- Oct 15, 2021
- Enrollment
- 12
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of PennsylvaniaLead sponsor
- University of PennsylvaniaOverall official - principal investigator
- VCN Biosciences, S.L.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.